

PROGRAM

Friday 23rd June 2023

Time	Event	Topic	Speaker
9.00am	Welcome and Acknowledgment of Country: Dr Kirsty Carey and Dr Jessica Duarte		
SESSION 1	CANCER GENOMICS <i>Sponsored by Cytek Biosciences</i>		
9.05am	Keynote	Illuminating the Hidden Cancer Transcriptome: Novel bioinformatics approaches to uncover structural rearrangements in RNA	Dr Nadia Davidson
9.35am	Oral 1	Identification of resistance mechanisms to YAP-TEAD inhibitors	Dr Aishwarya Kilkarni
9.50am	Oral 2	Genomic aberrations in ctDNA and clinical outcomes from [¹⁷⁷ Lu]Lu-PSMA-617 in advanced prostate cancer	Dr Heidi Fettke
10.05am	Oral 3	Evaluation of fixed single-cell/nuclei RNASeq technologies within brain cancer	Dr Zachery Moore
10.20am	Sponsor Presentation		Cytek Biosciences
10.25am	Short Talk 1	MYC as a regulator of dormancy in triple negative breast cancer	Dr Charlotte Roelofs
10.30am	Short Talk 2	Toblerone: Detecting exon deletion events in cancer using RNA-seq	Dr Andrew Lonsdale
10.35am	Short Talk 3	Deciphering epigenetic alterations in pre-leukemic stem cells during T-cell acute lymphoblastic leukemia development	Dr Alex (Feng) Yan
10.40am	Sponsor Presentation		Australian Biosearch
10.45am	Morning Break <i>sponsored by Australian Biosearch</i>		

SESSION 2	CANCER THERAPEUTICS <i>Sponsored by STEMCELL Technologies</i>		
11.15am	Keynote	Cracking the Code: Unveiling actionable targets for powerful cancer vaccines	Dr Pouya Faridi
11.45am	Oral 4	Targeting Ikaros family members, using CRISPR/Cas9 technology, improve CAR-T cells efficacy and persistence.	Dr Isabelle Munoz
12.00pm	Oral 5	The DCLK1 interactome reveals novel kinase dependent involvement in cell cycle processes.	Dr Annalisa Carli
12.15pm	Oral 6	Phospho-proteogenomic profiling of acute myeloid leukaemia to identify novel therapeutic targets	Dr Heather Murray
12.30pm	Sponsor Presentation		STEMCELL Technologies
12.35pm	Short Talk 4	Tumour suppressor <i>KEAP1</i> confers resistance to KRAS inhibitors	Dr Mara Zeissig
12.40pm	Short Talk 5	Ovarian cancer ascites suppresses CAR T cell mediated cytotoxicity.	Dr Sara Roth
12.45pm	Short Talk 6	p53 isoform expression promotes a stemness phenotype and drives therapy resistance in breast cancer.	Dr Luiza Reinhardt
12.50pm	Sponsor Presentation		Abcam
12.55pm	Lunch and Poster Session <i>sponsored by Abcam</i>		
SESSION 3	IMMUNOLOGY <i>Sponsored by Millenium Science</i>		
2:15pm	Sponsor Presentation		Millenium Science
2.20pm	Oral 7	Defining the off-target impacts of cancer immunotherapy on female reproductive function	Dr Amy Winship
2.35pm	Oral 8	CRISPR-HDR engineering of T cells for immunotherapy purposes	Dr Maria Nogueira de Menezes
2.50pm	Oral 9	$\gamma\delta$ T cells as potential modulators of SCLC tumour-specific responses	Dr Jin Ng
3.05pm	Oral 10	Combined with Flt3 ligand, IL-4 boosts generation of functional BM-derived cDC1 for immunotherapy	Dr Mitra Ashayeripanah
3.20pm	Consumer Panel		
3.50pm	Sponsor Presentation		Revvity
3.55pm	Awards Presentation and Final Remarks: Dr Kirsty Carey & Dr Jessica Duarte		
4.05pm	Close and Networking Event <i>sponsored by Revvity</i>		

